SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bhag Karamchandani who wrote (4773)7/7/1998 12:11:00 AM
From: Steve Fancy   of 6136
 
Bhag: Regarding AG3340, I double checked the report. The Anticipated Milestones were on the bottom of the last page, and listed in date order. In that this report was faxed to me, maybe I'm missing the last page. I'll check with the source in the morning and let you know.

One thing I noticed from my laymans standpoint regarding Remune:

...presented new data on Remune, showing dramatic increases in HIV immune stimulation indexes among patients who received the agent along with standard ART. Remune increased levels of circulating chemokines and increased virus-specific T helper cell counts. It also decreased virus blood levels.

They then go on to state the viral blood level statistics, but never explain or offer any statistics indicating how dramatic the increases in HIV immune stimulation indexes were, or how much levels of chemokines and virus-specific T helper cell counts were boosted, or in what percentage of patients. I wonder if this data is known, or its being kept under wraps.

I don't believe AGPH would enter into a deal unless they felt very strongly about it, but, if initial supporting data is not being released, I can see based on history, how investors might question their judgement. All three deals sound like they may be pretty big "ifs". Apparently this is just the way this industry works?

sf



Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News